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NeuritogenesisIt is increasingly recognised that chronically activated glia contribute to the pathology of various neurode-
generative diseases, including glaucoma. One means by which this can occur is through the release of neuro-
toxic, proinﬂammatory factors. In the current study, we therefore investigated the spatio-temporal patterns
of expression of three such cytokines, IL-1β, TNFα and IL-6, in a validated rat model of experimental
glaucoma.
First, only weak evidence was found for increased expression of IL-1β and TNFα following induction of ocular
hypertension. Second, and much more striking, was that robust evidence was uncovered showing IL-6 to be
synthesised by injured retinal ganglion cells following elevation of intraocular pressure and transported in an
orthograde fashion along the nerve, accumulating at sites of axonal disruption in the optic nerve head. Ver-
iﬁcation that IL-6 represents a novel marker of disrupted axonal transport in this model was obtained by
performing double labelling immunoﬂuorescence with recognised markers of fast axonal transport. The stim-
ulus for IL-6 synthesis and axonal transport during experimental glaucoma arose from axonal injury rather
than ocular hypertension, as the response was identical after optic nerve crush and bilateral occlusion of
the carotid arteries, each of which is independent of elevated intraocular pressure. Moreover, the response
of IL-6 was not a generalised feature of the gp130 family of cytokines, as it was not mimicked by another fam-
ily member, ciliary neurotrophic factor. Finally, further study suggested that IL-6 may be an early part of the
endogenous regenerative response as the cytokine colocalised with growth-associated membrane
phosphoprotein-43 in some putative regenerating axons, and potently stimulated neuritogenesis in retinal
ganglion cells in culture, an effect that was additive to that of ciliary neurotrophic factor. These data comprise
clear evidence that IL-6 is actively involved in the attempt of injured retinal ganglion cells to regenerate their
axons.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Glaucoma is a progressive, intraocular pressure (IOP)-sensitive optic
neuropathy with a poorly understood pathogenesis and limited treat-
ment options (Chidlow et al., 2007). The disease, which is the most
common cause of irreversible blindness worldwide (Quigley andmmon carotid arteries; APP,
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NC-ND license.Broman, 2006), is characterised by structural damage to the optic
nerve (ON) and the progressive death of retinal ganglion cells (RGCs).
Converging clinical (Quigley, 2011) and experimental (Howell et al.,
2007; Vidal-Sanz et al., 2011) data have led to a prevailing belief that
the primary site of injury in glaucoma occurs at the optic nerve head
(ONH). A recent study by ourselves corroborates this viewpoint: using
a validated, experimentally-induced ratmodel of glaucoma,we demon-
strated that the ONH is the pivotal site of axonal transport disruption
and axonal cytoskeletal damage following moderate elevation of IOP,
with subsequent anterograde degeneration of axons and retrograde
death of RGC somas (Chidlow et al., 2011b).
A number of theories have been proposed to account for the suscep-
tibility of theONH to glaucomatous injury. Of these, themost commonly
advocated are the “mechanical” and “vascular” theories (Fechtner and
Weinreb, 1994). The former hypothesis contends that elevated IOP
causes physical constriction to axon bundles, thereby disrupting axo-
plasmic transport (Burgoyne et al., 2005; Quigley, 1999). Damage to
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mechanically distorted local glia. The latter hypothesis proposes that
axonal and glial components of the ONH undergo chronic hypoxic or is-
chemic injury as a result of compromised local blood ﬂow, resulting
from either increased IOP or other risk factors that lead to vascular
dysregulation (Flammer et al., 2002; Yanagi et al., 2011). The ONH is
considered especially susceptible to a decreased nutrient supply
owing to its high density of mitochondria, which are required to serve
the considerable energy requirements of the unmyelinated axons of
the prelaminar and laminar ON (Barron et al., 2004).
A common element to both theories relates to the potential involve-
ment of resident ONH glial cells. Activated glia are increasingly suspected
to play a leading role in the pathogenesis of glaucoma (Bosco et al., 2011;
Hernandez et al., 2008; Johnson and Morrison, 2009; Yuan and Neufeld,
2001), but knowledge of the actual processes involved remains largely
speculative. Glial cells are known tomodify their gene expression proﬁles
in response to homeostatic imbalance, potentially triggering or exacerbat-
ing neuronal damage if persistently activated. One such mechanism by
which this can occur is via the synthesis and release of proinﬂammatory
cytokines, notably tumor necrosis factor-α (TNFα), interleukin (IL)-1β
and IL-6 (Hanisch, 2002). There exists persuasive evidence for the causal
involvement of glia-derived TNFα and IL-1β in the pathogenesis of white
matter injuries in the CNS induced by hypoxic and mechanical insults,
such as chronic cerebral hypoperfusion (Tomimoto et al., 2003), neonatal
hypoxia-ischemia (Deng et al., 2011) and spinal cord compression
(Esposito and Cuzzocrea, 2011). The situation regarding IL-6, however,
is less straightforward, with this cytokine exerting beneﬁcial as well as
detrimental effects depending on the pathological context (Suzuki et al.,
2009). In the eye, an accumulating body of data points to a detrimental
role for TNFα: the cytokine is toxic to both RGC somas (Berger et al.,
2008) and axons (Kitaoka et al., 2006; Nakazawa et al., 2006), and has
been shown to be upregulated by ONH glia in glaucomatous patients
(Yuan and Neufeld, 2000). Little is known about the involvement of
IL-1β and IL-6 in glaucoma, with cell culture studies suggesting a
neuroprotective role for IL-6 (Sappington et al., 2006).
The primary goal of the current study was to further our knowl-
edge of the pathology of experimental glaucoma by focussing on the
spatio-temporal patterns of expression of the proinﬂammatory cyto-
kines IL-1β, TNFα and IL-6. We hypothesised that the early disruption
to axonal homeostasis that occurs in our experimental glaucoma
model would correlate with an upregulation of proinﬂammatory cy-
tokines by resident glia, and, that the extent of expression would
rise during the subsequent axonal degeneration phase, concurrent
with increasing glial activity.
Materials and methods
Animals and procedures
This study was approved by the Animal Ethics Committees of the
Institute of Medical and Veterinary Science and the University of Ad-
elaide and conforms with the Australian Code of Practice for the Care
and Use of Animals for Scientiﬁc Purposes, 2004. All experiments also
conformed to the ARVO Statement for the Use of Animals in Ophthal-
mic and Vision Research. Adult Sprague–Dawley rats (200–250 g)
were housed in a temperature- and humidity-controlled environ-
ment with a 12-h light, 12-h dark cycle and were provided with
food and water ad libitum.
For establishment of experimental glaucoma, ratswere anaesthetised
with 100 mg/kg ketamine and 10 mg/kg xylazine. Ocular hypertension
was then induced in the right eye of each animal by laser photocoagula-
tion of the trabecular meshwork using a slightly modiﬁed protocol
(Ebneter et al., 2010) of the method described by Levkovitch-Verbin
et al. (2002). For 14 day rats, a second laser treatment was given on
day 7 if the difference in IOP between the two eyes was less than
8 mm Hg. IOPs were measured in both eyes at baseline, 8 h, day 1, day3, day 7 and day 14 using a rebound tonometer factory calibrated for
use in rats. All animals demonstrated an adequate IOP elevation (mini-
mum increase in IOP of 10 mm Hg) and therefore none were excluded
from the study. 3 animals were excluded as a result of death under an-
aesthesia and 3 due to hyphema. Two cohorts of rats were used in the
current study. The ﬁrst cohort was used for immunohistochemistry/
histology: the number of rats analysed at each time point was as follows:
8 h (n=5), 1 day (n=8), 3 days (n=9), 7 days (n=13), 14 days
(n=21). IOP data for these rats are provided (see Table 2). In addition,
3 rats were killed at 2 days and transverse sections taken through the
ONH, and, 5 rats were killed at 1 day and used for ELISA analysis. For ax-
onal tracing, 4 rats were injected intravitreally with 5 μl of 0.1%
AlexaFluor 594-conjugated cholera toxin β-subunit (CTB) dissolved in
sterile PBS. After 24 h, the right eyes were laser-treated as above. Rats
were killed after 2 days and tissues removed for immunohistochemistry.
The second cohort was used for RT-PCR. The number of rats analysed at
each time point was as follows: 1 day (n=7), 3 days (n=13), 7 days
(n=13), 14 days (n=7). The chiasm fromeach ratwas taken for immu-
nohistochemistry to verify that the procedure had induced an injury re-
sponse commensurate with the ﬁrst cohort.
For endotoxin-induced retinal inﬂammation, an intravitreal injection
of 0.2% lipopolysaccharide (LPS; 5 μl in sterile saline) was performed in
one eye. For excitotoxicity experiments, an intravitreal injection of
40 nmol of NMDA (5 μl in sterile saline) was performed in one eye. In
each case, the contralateral eye received 5 μl of sterile saline. All rats
(NMDA, n=4; LPS, n=4 for immunohistochemistry, n=4 for ELISA)
were killed after 6 h. ON crush was performed as previously described
(Chidlowet al., 2011b). In brief, the superiormuscle complexwas divided
and the ON exposed by blunt dissection. The ONwas then crushed 3 mm
posterior to the globe under direct visualisation using number 5 forceps
for 20 s. To avoid confusing retinal ischemic changes with the effects of
crush, the fundus was observed ophthalmologically immediately after
nerve crush, in order to discard any animals with perfusion dysfunction
as a result of surgery. A total of 12 rats were subjected to ON crush and
these were killed after either 1 day (n=6) or 14 days (n=6). Bilateral
occlusion of the common carotid arteries (2VO) was performed as previ-
ously described (Chidlow et al., 2010). In brief, rats were anaesthetised
and a ventral incision was made. The common carotid arteries were
then bilaterally separated from the carotid sheath and vagus nerve. The
arteries were ligated with silk sutures. Sham animals received the same
operationwithout occlusion of the vessels. A total of 4 ratswere subjected
to 2VO, which were killed after 2 days.
Tissue processing and histology
All rats were killed by transcardial perfusion with physiological
saline under deep anaesthesia. In those rats where tissue was not
taken for RT-PCR, perfusion with 4% (w/v) paraformaldehyde was
also subsequently undertaken. Each eye with ON, optic chiasm and
the proximal part of the optic tract attached was carefully dissected.
From the dissected tissue, a short piece of ON (2 mm long), 1.5 mm
behind the globe, was removed for resin embedding. The globe,
remaining ON, chiasm and proximal segment of optic tract were
ﬁxed in 10% buffered formalin for at least 24 h and then processed
for routine parafﬁn-embedding. Globes were embedded and sec-
tioned sagitally; ONs and chiasmata, longitudinally. In all cases,
4 μm serial sections were cut. As detailed above, 3 rats killed at
2 days were used for transverse sectioning of the ONH. The short
piece of proximal ON taken for resin sectioning and toluidine blue
staining was treated as previously reported (Ebneter et al., 2010).
Immunohistochemistry
Fluorescent immunohistochemistry was performed as previously
described (Chidlow et al., 2011a,b). Following deparafﬁnisation, anti-
gen retrieval was achieved by microwaving the sections in 10 mM
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3% normal horse serum and incubated overnight in primary antibody,
followed by consecutive incubations with biotinylated secondary an-
tibody and streptavidin-conjugated AlexaFluor 594. Sections were
mounted using anti-fade mounting medium. Speciﬁcity of antibody
labelling was conﬁrmed by incubating adjacent sections with mouse
IgG1 isotype controls for monoclonal antibodies, or normal rabbit/
goat serum for polyclonal antibodies. Primary antibody details are
provided in Supplementary Table 1. To conﬁrm the validity of nega-
tive ﬁndings, the following alternate antibodies were also tested: rab-
bit anti-IL-1β (ab9787, Abcam); rabbit anti-TNFα (HP8001, Hycult).
For double labelling ﬂuorescent immunohistochemistry, visualisa-
tion of one antigen was achieved using a 3-step procedure (primary
antibody, biotinylated secondary antibody, streptavidin-conjugated
AlexaFluor 594), whilst the second antigen was labelled by a 2-step
procedure (primary antibody, secondary antibody conjugated to
AlexaFluor 488). Sections were prepared as above, then incubated
overnight at room temperature in the appropriate combination of pri-
mary antibodies. On the following day, sections were incubated with
the appropriate biotinylated secondary antibody (1:250) for the
3-step procedure plus the correct secondary antibody conjugated to
AlexaFluor 488 (1:250, Invitrogen) for the 2-step procedure for
30 min, followed by streptavidin-conjugated AlexaFluor 594 (1:500)
for 1 h. Sections were then mounted using anti-fade mounting medi-
um and examined under a confocal ﬂuorescence microscope.
ONH accumulation of β-amyloid precursor protein (APP), IL-6 and
growth-associated membrane phosphoprotein-43 (Gap43) was assessed
semi-quantitatively using a 5-point grading system, ranging from 0 =
undetectable to 4 = numerous intensely-stained immunopositive axons
covering a substantial area of the prelaminar to post-laminar ONH. Statis-
tical analysis of APP grade vs IL-6 gradewas byWilcoxon signed-rank test
with modiﬁed Bonferroni correction.
Terminal deoxynucleotidyl transferase (TdT)-mediated, dUTP nick
end labelling (TUNEL) was performed as described previously
(Chidlow et al., 2009).
ELISA
The level of IL-6 in retinal samples was estimated using an
enzyme-linked immunosorbent assay (Quantikine®, R&D Systems).
Retinas from control, LPS-treated, and experimental glaucoma rats
were carefully dissected, immediately sonicated in PBS containing pro-
tease inhibitors, then snap frozen and stored at−70 °C. On the day of
the assay, samples were thawed, centrifuged at 13,000 ×g, and the su-
pernatant extracted for use in ELISA and for protein measurement.
The ELISA assay was conducted according to instructions, whilst the
amount of protein was determined using a routine methodology.
Electrophoresis/Western blotting
Electrophoresis/Western blotting was performed as previously
described (Chidlow et al., 2010). In brief, recombinant proteins for
rat TNFα (510-RT-050), rat IL-1β (510-RL-050) and rat IL-6
(506-RL-050) were obtained (RnD Systems) and diluted to provide
samples containing 1, 10 and 10 ng of each protein. After electropho-
resis, samples were transferred onto PVDF membranes. Following a
block of non-speciﬁc binding, blots were probed by sequential incu-
bations with primary antibodies (Supplementary Table 1), appropri-
ate secondary antibodies conjugated to biotin, and streptavidin–
peroxidase conjugate. Blots were then developed and the images
captured.
Real-time RT-PCR
Reverse-transcription polymerisation chain reaction (RT-PCR) stud-
ies were carried out as described previously (Chidlow et al., 2008). Inbrief, retinas were dissected, total RNA was isolated and ﬁrst strand
cDNAwas synthesised from 2 μg DNase-treated RNA. Real-time PCR re-
actions were carried out in 96-well optical reaction plates using the
cDNA equivalent of 20 ng total RNA for each sample in a total volume
of 25 μl containing 1× SYBR Green PCR master mix (BioRad), forward
and reverse primers at a ﬁnal concentration of 400 nM. The thermal cy-
cling conditions were 95 °C for 3 min and 40 cycles of ampliﬁcation
comprising 95 °C for 12 s, 63 °C for 30 s and 72 °C for 30 s. Primer
sets used were as follows (sense primer, antisense primer, product
size, accession number): GAPDH (5′-TGCACCACCAACTGCTTAGC-3′,
5′-GGCATGGACTGTGGTCATGAG-3′, 87 bp, GenBank ID: NM_017008),
TNFα (5′-AAATGGGCTCCCTCTCATCAGTTC-3′, 5′-TCTGCTTGGTGGTTTG
CTACGAC-3′, 111 bp, GenBank ID: NM_012675), IL-1β (5′-CACCTCTCAA
GCAGAGCACAG-3′, 5′-GGGTTCCATGGTGAAGTCAAC-3′, 79 bp, GenBank
ID: NM_031512), IL-6 (5′-TGCCTATTGAAAATCTGCTCTGG-3′, 5′-ATTGGA
AGTTGGGGTAGGAAGG-3′, 189 bp, GenBank ID: NM_012589). Results
obtained from the real-time PCR experiments were quantiﬁed using the
comparative threshold cycle (CT) method (ΔΔCT) for relative quantita-
tion of gene expression (Livak and Schmittgen, 2001), corrected for am-
pliﬁcation efﬁciency (Pfafﬂ, 2001). All values were normalised using the
endogenous housekeeping gene GAPDH and expressed relative to con-
trols. Statistical analysis was carried out by ANOVA followed by
post-hoc Scheffe test. The null hypothesis tested was that CT differences
between target and housekeeping genes would be the same in control
and experimental retinas.
Adult rat RGC cultures
Adult Sprague–Dawley rats were euthanised by CO2 asphyxiation
and their eyes enucleated. The retina from each eye was dissected, cut
into small pieces, incubated in activated papain solution (2 mg/ml pa-
pain, 0.4 mg/ml DL-cysteine, 0.4 mg/ml bovine serum albumin, in
Neurobasal medium) for 25 min at 37 °C and then washed three
times with RGC culture medium (Neurobasal medium with B27 nutri-
ent supplement, 100 U/ml penicillin, 100 U/ml streptomycin, 1 mMso-
dium pyruvate, 2 mM L-glutamine, 5 μg/ml insulin, 100 μg/ml
transferrin, 100 μg/ml bovine serum albumin, 60 ng/ml progesterone,
16 μg/ml putrescine, 40 ng/ml sodium selenite, 40 ng/ml L-thyroxine,
40 ng/ml tri-iodothyronine, 5 μM forskolin and 1% [v/v] foetal bovine
serum). Retinal pieces were triturated by gently passing through
ﬁre-polished disposable glass Pasteur pipettes until full cell dispersion
had taken place. Cell suspensions were dispensed onto 13 mm borosil-
icate glass coverslips previously coated sequentially with poly-D-lysine
(5 μg/ml, overnight) and laminin (1 μg/ml, 90 min) at the density of ap-
proximately 1×106 cells per well. In general, cells were cultured in RGC
culture medium plus growth factor mix (50 ng/ml BDNF, 10 ng/ml
CNTF, 10 ng/ml bFGF) at 37 °C, with saturating humidity and 5% (v/v)
CO2, for up to 30 days, and with medium being changed every 3 days
after the ﬁrst 7 days in vitro.
Cells were treated with growth factors, including with recombi-
nant rat IL-6 (1.33 μg/ml) from day zero (harvesting day) onwards.
The study design included four groups delineated as follows: (1) no
growth factor mix and no IL-6, (2) growth factor mix with no IL-6,
(3) no growth factor mix but plus IL-6, (4) plus growth factor mix
and IL-6. This treatment regime enabled determination of whether
IL-6 could instigate neuritogenesis or could only assist propagation
of existing neurite buds (as stimulated by growth factor mix). Cells
on coverslips were ﬁxed 7 days after culture/treatment with 10%
buffered formalin and then were immunocytochemically double la-
belled with rabbit anti-tau, which labelled cell bodies and all neurites,
and mouse anti-GAP43, which labelled all new growing neurites. Cov-
erslips were mounted face-side down and microscopically analysed
with immunoﬂuorescence optics. To quantify the effect of IL-6 on
neuritogenesis, triplicate coverslips were treated with the additives
described above, from four individual cultures. From each coverslip,
eight individual RGCs were selected and analysed using the Simple
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analysed, parameters which were determined were the number of
neurites branching out from the perikaryon and the mean length of
the major neurite (rounded to the nearest 25 μm). Statistical analysis
was by Kruskal–Wallis one-way analysis of variance, followed by
Dunn's Multiple Comparison Test.
Results
Validation of the IL-1β, TNFα and IL-6 antibodies
Acquisition of biologically meaningful immunohistochemical data
from parafﬁn-embedded tissue requires the use of validated anti-
bodies within the context of an optimised methodology. Publication
of false-negative and -positive ﬁndings in the ﬁeld of Neuroscience
is of legitimate concern (Saper 2005; Rhodes and Trimmer 2006;
Fritschy 2008). Initially, therefore, we sought to verify that the select-
ed antibodies recognised their appropriate targets, and, that each
yielded high signal-to-background labelling. To achieve this aim, we
performed Western blotting of recombinant rat IL-1β, TNFα and
IL-6 proteins with the antibodies in question. Next, we analysed reti-
nal sections from control eyes and from eyes injected with the
proinﬂammatory endotoxin LPS, which is known to induce microglia
to synthesise IL-1β, TNFα and IL-6 (Mertsch et al., 2001). The LPS tis-
sue acted as a positive control, since expression of IL-1β, TNFα and
IL-6 is minimal in control retinas. Supplementary Fig. 1 shows results
obtained with the selected IL-1β and TNFα antibodies. Both anti-
bodies detected concentration-dependent, single proteins at the
expected molecular weights. LPS induced upregulation of both mole-
cules within discrete populations of cells in the inner retina. Double
labelling with the microglial-speciﬁc marker iba1 indicated that ex-
pression of each of the cytokines was, as expected, restricted to this
cell type.
Four different IL-6 antibodies (see Supplementary Fig. 2) were
analysed for their utility. Western blotting of recombinant rat IL-6
indicated that three of the four antibodies produced clean,
concentration-dependent bands at the correct molecular weight
(Supplementary Fig. 2). Next we assessed immunolabelling in
parafﬁn-embedded retinal sections. None of the four antibodies
showed any immunoreactivity in sections from control animals
(data not shown). One of the antibodies (R&D Systems, cat#
AF506) discretely labelled a population of cells in the LPS-treated
retina with a high signal-to-noise ratio. Successful colocalisation
with iba1 and IL-1β demonstrated that these cells are activated mi-
croglia. Immunolabelling was abolished in the absence of secondary
antibody and was abolished by preadsorption with the recombinant
IL-6 protein (Supplementary Fig. 3). The other three antibodies failed
to provide positive immunolabelling in LPS-treated retinas (Supple-
mentary Fig. 4). As such, they were not used in the remainder of the
study.
Expression of IL-1β, TNFα and IL-6 by microglia after NMDA-induced
excitotoxicity
Prior to investigating the association of IL-1β, TNFα and IL-6 with
experimental glaucoma, we examined expression of the cytokines
following N-methy-D-aspartate (NMDA) treatment. NMDA-induced
excitotoxicity is the classical method of inducing somato-dendritic
death of RGCs. As such, the results assist contextualizing those
obtained from the experimental glaucomamodel, which causes initial
damage to RGC axons at the site of the ONH rather than to the
perikarya (Chidlow et al., 2011b). The results obtained were very sim-
ilar to those yielded after LPS treatment, namely rapid (i.e. by 6 h) in-
ductions of all three cytokines, with expression limited to microglia
located in the inner retina (Fig. 1). At 1 day after NMDA treatmentmicroglia were no longer observed to express IL-1β, TNFα and IL-6
(data not shown).
Temporal analysis of IL-1β, TNFα and IL-6 mRNA expression during ex-
perimental glaucoma
To elucidate the timing and extent of any changes in expression of
IL-1β, TNFα and IL-6 in the retina following elevation of raised IOP,
we quantiﬁed the mRNAs encoding these proteins using real-time
RT-PCR (Fig. 2). Expression of IL-1β mRNA was unaltered at 24 h
after induction of ocular hypertension, the earliest time point
analysed. Thereafter, the IL-1β mRNA level in the retina was found
to be consistently greater in the treated animals than in the control
group (3.5-fold higher at 3 days, 3.8-fold higher at 7 days, 4.3-fold
higher at 14 days). Each of these differences was statistically signiﬁ-
cant. The level of TNFα in treated retinas was statistically higher
than in controls at all four time points analysed with the largest dif-
ferential between treated and control animals (3.9-fold) occurring
24 h after laser-treatment. IL-6 mRNAwas more robustly upregulated
than either IL-1β or TNFα mRNAs in response to elevated IOP. At
24 h, IL-6 mRNA in treated retinas was 7.4-fold higher than in the
control group. Thereafter, the level of IL-6 mRNA gradually dimin-
ished over time.
Expression of IL-1β and TNFα during experimental glaucoma
Retina
Despite the evidence of moderate IL-1β and TNFα mRNA
upregulations in response to elevated IOP, analysis of the correspond-
ing immunoreactivities failed to reveal any positive cellular labelling
in any of the animals at any of the time points analysed, which ranged
from 8 h to 14 days (Figs. 3A,B). For example, at 24 h after induction
of ocular hypertension, no TNFα immunoreactivity was observed in
iba1-positive microglia, or in astrocytes or Müller cells, both of
which featured enhanced expression of the intermediate ﬁlament
GFAP, or in neurons. Similarly, at 14 days, a time point when signiﬁ-
cant RGC death has occurred (Chidlow et al., 2011b) and activated
iba1-positive microglia are numerous, no IL-1β immunoreactivity
was detectable in any retinal cell type.
Optic nerve head
We have recently shown that the earliest indication of damage fol-
lowing chronic elevation of IOP is axonal transport failure within RGC
axons as they pass through the ONH (Chidlow et al., 2011b). Since mi-
croglia are rapidly activated by even minor homeostatic imbalance, it
is of interest to determine whether this event, or the axonal cytoskel-
etal damage that occurs subsequently, triggers increased expression
of the proinﬂammatory cytokines IL-1β and TNFα. The results indi-
cate not. At 24 h (Fig. 3C), widespread accumulation of APP was evi-
dent in injured axons in the ONH of treated eyes, but no expression of
IL-1β or TNFα was detectable. Similarly, after 3 days of raised IOP
(Fig. 3D), when the number of microglia in the ONH had increased
and the majority of these cells displayed an activated morphology
(Ebneter et al., 2010), there was no discernible expression of IL-1β
or TNFα. Analysis of animals killed at later time points produced the
same results. In order to verify that these negative ﬁndings were gen-
uinely representative, we probed sections with alternate IL-1β and
TNFα antibodies (see Materials and methods) that we had previously
validated in LPS-injected eyes. As expected, the results were identical
(data not shown).
Expression of IL-6 during experimental glaucoma
Immunolabelling for IL-6 in rats subjected to experimental glauco-
ma produced results as striking as they were unexpected. Following
induction of elevated IOP, expression of IL-6 was associated not
with glia, but with injured RGC axons (see Figs. 4–6). As early as 8 h
Fig. 1. Double labelling immunoﬂuorescence of IL-1β (A–C), TNFα (D–F) and IL-6 (G–I) with the microglia marker iba1 in rat retinas at 6 h after NMDA-induced excitotoxicity. The
majority of iba1-positive microglia are immunoreactive to IL-1β. In contrast, substantially fewer iba1-positive microglia express either TNFα or IL-6. No expression of IL-1β, TNFα or
IL-6 is observed in other cell types. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer. Scale bar: 25 μm.
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By 24 h, intense IL-6 immunoreactivity was observed throughout
the ONH, a result that was typical of the majority of rats analysed
within the ﬁrst few days (Figs. 4A, 5A–C). Labelling of transverse sec-
tions of the ONH and proximal ON in rats that had undergone 2 days
of elevated IOP revealed an asymmetric, regionalised pattern of IL-6
expression within the unmyelinated laminar segment of the nerve
(Fig. 4B), but no presence distal to this site in the myelinated portion
of the ON (Fig. 4B) and optic tract (data not shown). The abundance
of IL-6 immunoreactivity in the ONH progressively diminished at
7 days and 14 days (Fig. 4A), paralleling the decline in IOP. In the ret-
ina, IL-6 immunoreactivity was barely detectable in control eyes, but
was upregulated in RGC somas that had been subjected to a week of
elevated IOP and was visible in some axons in the nerve ﬁbre layer
(Fig. 4C).Fig. 2. Temporal characterisation of the levels of TNFα, IL-1β and IL-6 mRNAs in the retina f
RT-PCR. Values (represented as mean±SEM) are normalised for GAPDH and expressed relat
Scheffe test, where n=40 (control), n=7 (1 day), n=13 (3 days), n=13 (7 days), n=7 (In order to verify the results from the immunohistochemistry exper-
iments, which documented a striking upregulation of IL-6 by 24 h after
induction of raised IOP, and, to provide a more quantitative analysis of
the level of IL-6 protein expression, we performed an ELISA. The results,
displayed in Table 1, conﬁrm that the retinal level of IL-6 is signiﬁcantly
elevated when compared with unlasered retinas.
The overall pattern of IL-6 immunoreactivity during experimental
glaucoma displayed a remarkable similarity to that of the stereotypical
marker of fast axonal transport, APP (Chidlow et al., 2011b), arguing
strongly that IL-6 is synthesised by RGCs following elevation of IOP
and transported in an orthograde fashion along the nerve until accumu-
lating at sites of axonal disruption in the ONH. To investigate whether
IL-6 is indeed a novel marker of disrupted axonal transport in this
model, we performed double labelling experiments with various axonal
and glialmarkers in rats that had undergone chronic ocular hypertension.ollowing induction of experimental glaucoma, as determined by quantitative real-time
ive to the control group. **Pb0.01, ***Pb0.001 by one-way ANOVA followed by post-hoc
14 days).
Fig. 3. Representative images of Il-1β and TNFα expression in the retina and ONH during experimental glaucoma. At 1 day after induction of chronic ocular hypertension (A, C),
retinal astrocytes and Müller cells display enhanced GFAP expression (A), whilst accumulation of APP (C, arrows) is evident within axons in the ONH. Iba1-positive microglia in
both regions are sparse and appear morphologically normal (A, C). No positive labelling for either Il-1β or TNFα is observed in the retina or ONH at this time point. At 3 days
after induction of chronic ocular hypertension (D), iba1-positive microglia in the ONH are numerous and display an activated morphology; however, they remain negative for
Il-1β and TNFα. By 14 days after induction of chronic ocular hypertension (B), iba1-positive microglia are abundant within the inner retina, but positive labelling for Il-1β and
TNFα is similarly not discernible. GCL, ganglion cell layer; INL, inner nuclear layer; ret, retina; APP, β-amyloid precursor protein. Scale bar: A, B, D, 25 μm; C, 50 μm.
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light, revealed an overlap of immunoreactivities, whichwas particularly
evident in injured axons displaying neuroﬁlament abnormalities
(Figs. 5D–F). Colabelling of IL-6 with recognised endogenous markers
of fast axonal transport, including APP (Figs. 5G–I) and synaptophysin
(data not shown), and with the neural tracer cholera toxin β-subunit
(CTB; Figs. 5J–L) also demonstrated that IL-6 colocalised with all three
axonal markers. In contrast, there was no colocalisation between IL-6
and the microglial marker iba1 (Figs. 6A–C), between IL-6 and the
Müller cell marker glutamine synthetase (Figs. 6D–F) and between IL-6
and the astrocyticmarker GFAP (Figs. 6G–I), indicating that IL-6 immuno-
reactivity likely resided solely within axons.
To provide a direct, quantitative comparison between IL-6 and
APP, representative sections from the central ONH of every rat
were labelled for both markers and graded for abundance of immu-
noreactivity using a 5 point grading scheme (see Materials and
methods). The results showed an excellent agreement between
IL-6 and APP at the 24 h, 1 day, 3 days and 7 days time points
(Table 2; P>0.5 by Wilcoxon signed-rank test with modiﬁed
Bonferroni correction for APP versus IL-6 at each of the time points;
r=0.85, Pb0.001 by Spearman's Rank correlation for the combineddata). Interestingly, however, at the 14 days time point, IL-6 was sig-
niﬁcantly more abundant than APP (Pb0.05 by Wilcoxon signed-
rank test with modiﬁed Bonferroni correction), suggesting that at
this later time point IL-6 may not simply represent a marker of axo-
nal transport disruption.
Expression of CNTF during experimental glaucoma
IL-6 is a member of the family of cytokines, with overlapping, pleio-
tropic activities, that all induce signalling through the common trans-
membrane receptor subunit gp130 (Suzuki et al., 2009). To elucidate
whether the response of IL-6 during experimental glaucoma is a gener-
alised feature of the gp130 family of cytokines, we investigated expres-
sion of an additional, widely-studied member of the family, ciliary
neurotrophic factor (CNTF). In normal adult rat retinas, CNTF immuno-
reactivity was localised to astrocytes and, to a lesser extent, Müller
cells (Fig. 7A). Following induction of elevated IOP, upregulated ex-
pression of CNTF was observed in both glial cell types, but no immu-
noreactivity was associated with neurons (Figs. 7B,C). In the ONH
and proximal ON of normal rats, CNTF expression was likewise re-
stricted to glial cells (Figs. 7D,G). After induction of experimental glau-
coma, modest upregulation of CNTF signal was observed in glial cell
Fig. 4. Localisation of IL-6 to injured RGC axons during experimental glaucoma. (A) Accumulation of IL-6 at the ONH at various times following induction of experimental glaucoma. In
normal rats, minimal IL-6 is associated with RGC axons. By 8 h after induction of chronic ocular hypertension, accumulation of IL-6 is evident within some axons in the pre- and
post-laminar ONH (arrows). At 24 h, intense IL-6 immunoreactivity is typically observed throughout the ONH. Analysis of rats at 3 days and 7 days shows IL-6 immunolabelling in the
ONH remains high, although not aswidespread as 1 day. By 14 days, few axons are immunopositive for IL-6. Ret, retina. (B) IL-6 accumulation is restricted to theONHduring experimental
glaucoma. Three levels of the ON of a typical 2 day rat are shown. A transverse section taken through the unmyelinated neck region (lamina) showswidespread IL-6 immunolabelling. In
contrast, sections takenmore distally through themyelinatedmedial ON and optic chiasmare negative for IL-6. (C) Localisation of IL-6within the retina during experimental glaucoma. In
normal rats, only low intensity IL-6 is associatedwith RGC somas. By 7 days after induction of chronic ocular hypertension, RGC somas and their axons (arrows) within the central nerve
ﬁbre layer display enhanced immunoreactivity for IL-6 (arrows). GCL, ganglion cell layer; INL, inner nuclear layer. Scale bars: A and B, 100 μm; C, 50 μm.
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axonal transport (Fig. 7F).
Expression of IL-6 in other models of RGC axonal injury
The results detailed above show that IL-6 is synthesised by RGCs
during experimental glaucoma and that this factor accumulates at
sites of axonal disruption in the ONH; however, it is unknown wheth-
er the signalling pathway that induces expression of IL-6 by RGC
somas derives from elevated IOP per se or from retrograde signals
emanating from the nerve at the site of injury. To address this issue,
we investigated IL-6 expression after ON crush (Fig. 8A, Table 2)
and bilateral occlusion of the common carotid arteries (2VO;
Fig. 8B). ON crush causes axonal damage via mechanical trauma at
the lesion site in the proximal ON, whilst 2VO drastically affects the
vascular supply to the proximal ON, producing an infarct (Chidlow
et al., 2010). Importantly, both models cause damage to the proximal
ON without elevating IOP.
At 1 day after ON crush, extensive accumulation of the axonally-
transported proteins APP and synaptophysin could be observed prox-
imal to the crush site; IL-6 accumulated in an analogous manner. APPand synaptophysin could also be seen accumulating on the distal side
of the lesion, indicating that these proteins are also normally
transported retrogradely along the ON. IL-6, in contrast, was not de-
tectable on the distal side of the lesion, suggesting that the cytokine
is not routinely transported bilaterally (Fig. 8A). At 14 days after ON
crush, little axonal APP immunoreactivity remained; however, as
was the case in experimental glaucoma, IL-6-positive axons were
still frequently observed at this later time point. Grading of ON sec-
tions veriﬁed that IL-6 was signiﬁcantly more abundant than APP
(Pb0.05 by Wilcoxon signed-rank test with modiﬁed Bonferroni
correction; Table 2).
At 2 days after 2VO, TUNEL labelling highlighted the appearance
of an infarct in the proximal ON, just distal to the ONH (Fig. 8B).
IL-6 and APP were both observed to accumulate within RGC axons
proximal to the infarct (Fig. 8B) in a similar manner to that observed
during ON crush and experimental glaucoma.
Relationship between IL-6 and Gap43 following optic nerve injury
Following ON crush, rat RGCs attempt to repair/regenerate their
damaged axons (Blaugrund et al., 1993; Doster et al., 1991; Leon et al.,
Fig. 5. Bright ﬁeld images of IL-6 labelling, and, double labelling immunoﬂuorescence of IL-6 with axonal markers in representative rats during experimental glaucoma. (A–C) Bright
ﬁeld images of IL-6 staining in two regions of the ONH at 2 days after induction of chronic ocular hypertension. (D–F) At this time point, IL-6 colocalises with the axonal structural
marker, neuroﬁlament light. (G-I) IL-6 also colocalises with APP, a marker of fast axonal transport, as seen in this rat killed at 7 days. (J–L) Following induction of chronic ocular
hypertension, the neural tracer CTB, which is taken up exclusively by RGCs, accumulates within axons throughout the ONH. IL-6 colocalises with CTB. APP, β-amyloid precursor
protein; CTB, cholera toxin β-subunit. NFL, neuroﬁlament light; ret, retina. Scale bars: 100 μm.
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is traditionally achieved by immunolabelling for Growth-Associated
Protein 43 (Gap43). We have recently shown that a similar phenome-
non occurs during experimental glaucoma,with regenerative ﬁbres fail-
ing to progress further than the ONH (Chidlow et al., 2010). We
hypothesised that induction of IL-6 following axonal injury may be an
early part of the endogenous axonal regenerative process. To explore
this possibility, weﬁrst compared expression of IL-6 and Gap43 after in-
duction of elevated IOP and ON crush in order to ascertain whether IL-6
is localised to regenerating axons (Figs. 9 and 10). Subsequently, we in-
vestigated the effect of administering IL-6 on Gap43-positive, neurite
growth in tissue culture (Fig. 11).
At 24 h after induction of raised IOP, RGCs axons at the ONH fea-
tured abundant IL-6 immunoreactivity, but minimal Gap43 immunore-
activity (Fig. 10). By 3 days, limited Gap43 expressionwas detectable in
IL-6 positive axons of some rats at the level of the prelaminar ONH
(Figs. 9A,B; Fig. 10). By 7 days, Gap43 expression had increased consid-
erably, such that it was typically more abundant than IL-6 within axons
in the ONH (Figs. 9C–F; Fig. 10). By 14 days, therewere usually substan-
tially more Gap43-positive axons than IL-6-labelled axons; however,colocalisation of the two markers was still evident in some ﬁbres, both
in the prelaminar ONH and the lamina (Figs. 9G–K; Fig. 10).
At 1 days after ON crush, axons proximal to the crush site were al-
ways Gap43-negative, but IL-6- and APP-positive (Gap43 grade 0.0±
0.0; IL-6 grade 4.0±0.0; APP grade 4.0±0.0). By 14 days, axons prox-
imal to the crush site were always Gap43-positive, frequently IL-6
positive, but rarely APP-positive (Gap43 grade 3.8±0.2; IL-6 grade
2.6±0.3; APP grade 1.5±0.3).
Effect of IL-6 on neuritogenesis of adult RGCs in culture
The overall data indicated that IL-6 was upregulated by injured
axons prior to Gap43 and continued to be expressed, to a lesser extent,
during the regenerative process. Evidence obtained from the study of
spinal axons supports the notion that conditional injury-induced
upregulation of IL-6 facilitates an environment favourable to axonal re-
generation (Cafferty et al., 2004; Cao et al., 2006). To establish whether
IL-6 directly promotes growth of RGC axons, we investigated the effect
of administering IL-6 on neuritogenesis in cultured adult RGCs.
Two experimental regimes were tested: the effect of IL-6 alone,
in order to determine whether this factor could actually initiate
Fig. 6. Double labelling immunoﬂuorescence of IL-6 with glial markers in representative rats killed at 2 days after induction of experimental glaucoma. IL-6 fails to colocalise with
the microglial marker iba1 (A–C). There is also no colocalisation with the Müller cell marker glutamine synthetase in the retina or prelaminar ONH (D–F). Three representative
images are shown of IL-6 double labelling with the astrocytic marker GFAP: (G) displays the prelaminar ONH; (H) highlights the neck/transition region of the ONH; (I) shows
the neck region of the ONH in transverse orientation. In none of these images is there any obvious colocalisation of IL-6 with GFAP. Glut Syn, glutamine synthetase; ret, retina.
L, longitudinal; TS, transverse. Scale bar: 100 μm.
Table 2
Grading of IL-6 and APP immunoreactivities at various times after induction of exper-
imental glaucoma and optic nerve crush.
Glaucoma Cont eyes 1 day
(n=7)
3 days
(n=8)
7 days
(n=13)
14 days
(n=21)
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cocktail of growth factors (Pang et al., 2007), to delineate whether it
couldmerely enhance or assist in the extension of already-instigated ﬁ-
bres. Results are shown in Fig. 11. After 7 days in culture, there were
very few RGCs present with neurites of more than 200 μm in length
when neither IL-6 nor the growth factor cocktail had been applied.
The presence of IL-6 signiﬁcantly enhanced both neuritogenesis, as de-
lineated by increased numbers of neurites emanating from the cell
perikarya, and neurite extension, as determined by quantifying neurite
lengths. In addition, the presence of the growth factor cocktail led to a
marked increase in both neurite numbers and their mean length, and
this was further signiﬁcantly enhanced by IL-6.
Discussion
It is increasingly recognised that chronically activated glia contrib-
ute to the pathology of various neurodegenerative diseases, including
glaucoma. One means by which this can occur is through the release
of neurotoxic, proinﬂammatory factors (Lull and Block, 2010). In
the current study, we investigated the spatio-temporal patterns ofTable 1
Level of IL-6 protein in the retina at 6 h after LPS treatment and 1 day after experimen-
tal glaucoma.
Treatment IL-6 level (expressed as pg IL-6
per μg protein)
Control 0.013 ± 0.003
LPS 0.078⁎ ± 0.020
Experimental glaucoma 0.043⁎ ± 0.018
⁎ Pb0.05 by unpaired t-test, where n=5 (control), n=4 (LPS), n=5 (experimental
glaucoma).expression of three such cytokines, IL-1β, TNFα and IL-6, in a validat-
ed rat model of experimental glaucoma. We had envisaged that resi-
dent glia, particularly those located within the ONH – the pivotal site
of injury during experimental glaucoma (Buckingham et al., 2008;
Chidlow et al., 2011b; Howell et al., 2007; Jakobs et al., 2005;
Martin et al., 2006; Salinas-Navarro et al., 2010) – would respond to
progressive axonal injury with a co-ordinated upregulation of these
cytokines. The overall results of the study were, therefore, surprising:
we found only weak evidence for synthesis of IL-1β and TNFα follow-
ing induction of ocular hypertension; however, we uncovered evi-
dence that IL-6 is expressed by injured RGCs and transported within
axons to the site of damage within the ONH. As shown by dataIntegral ΔIOP⁎ – 16.6±1.9 46.4±11.4 91.5±8.8 186.7±12.4
Maximal ΔIOP⁎ – 24.3±3.9 26.6±4.9 25.5±1.9 25.8±1.1
Terminal ΔIOP⁎ – 22.0±3.4 14.4±6.4 9.3±1.9 6.0±1.1
APP grade 0.0±0.0 3.7±0.2 3.0±0.3 2.3±0.2 1.5±0.1
IL-6 grade 0.0±0.0 3.6±0.3 3.0±0.3 2.5±0.2 2.0†±0.2
Optic nerve
crush
Cont eyes 1 days
(n=6)
3 days 7 days 14 days (n=8)
APP grade 0.0±0.0 4.0±0.0 – – 1.5±0.3
IL-6 grade 0.0±0.0 4.0±0.0 – – 2.6†±0.3
ΔIOP⁎, calculated as IOP of treated eye — IOP of untreated contralateral eye and
expressed in mm Hg. †Pb0.05 (APP grade vs IL-6 grade) by Wilcoxon signed-rank
test with modiﬁed Bonferroni correction.
Fig. 7. Representative images of CNTF expression in the retina and optic nerve of control rats and in rats subjected to experimental glaucoma. In the normal retina (A), CNTF im-
munoreactivity is predominantely associated with astrocytes (small arrow), although some Müller cell somas (large arrow) and radial processes (arrowhead) are delicately la-
belled. At 7 days after induction of chronic ocular hypertension (B), upregulated CNTF expression is discernible in both retinal cell types. CNTF colocalises with the Müller cell
marker glutamine synthetase (C). In the ONH (D) and proximal ON (G) of normal rats, CNTF is expressed by glial cells. During experimental glaucoma, only minor upregulation
of CNTF in the ONH (E) and proximal ON (H) is noted. CNTF colocalises almost totally with the small heat shock protein αB-crystallin (F). In contrast, there is no presence of
CNTF within injured axons, as indicated by the lack of colocalisation with APP. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; ret, retina; CNTF ciliary
neurotrophic factor; Glut Syn, glutamine synthetase; APP, β-amyloid precursor protein; αB-crys, αB-crystallin. Scale bars: A–C and G–I, 25 μm; D–F, 50 μm.
577G. Chidlow et al. / Neurobiology of Disease 48 (2012) 568–581obtained from alternative models, injury to the ON, rather than ele-
vated IOP, appeared to be the stimulus for IL-6 upregulation. Further-
more, the response was not characteristic of cytokines in the gp130
family. We further showed that IL-6 colocalised with Gap43 in
some putative regenerating axons and that this cytokine induced
neuritogenesis in RGC cultures, supporting the view that IL-6 is in-
volved in the post-trauma attempts of injured RGCs to regenerate
their axons.
IL-6 is normally present at low levels in the CNS, but is upregulated
in numerous acute and chronic neurodegenerative conditions. Astro-
cytes, microglia and neurons have all been shown to be sources of the
cytokine in differing circumstances (Spooren et al., 2011). In the retina,
IL-6 is expressed by microglia during ischemia–reperfusion injury
(Sanchez et al., 2003) and, as shown in the present study,
NMDA-induced excitotoxicity and endotoxin challenge. In addition, cul-
tured microglia increase IL-6 release when subjected to raised hydro-
static pressure (Sappington et al., 2006). It is evident, therefore, that
microglia are the dominant retinal cell type responsible for IL-6 synthe-
sis following acute neuroinﬂammatory injuries. The most striking ﬁnd-
ing in the present study was the observation that not only was IL-6
detected in RGCs, but that it also underwent orthograde axonal trans-
port following injury to the ON, such as occurs during experimental
glaucoma and ON crush, accumulating at sites of axonal disruption.
The patterns of IL-6 immunoreactivity during the ﬁrst 7 days after ON
injury were essentially identical to those of APP, the well-studied and
conventional endogenous marker of axonal transport disruption in the
ON (Chidlow et al., 2011b; Morin et al., 1993). In fact, IL-6 afforded su-
perior signal-to-background immunolabelling comparedwith APP. This
is possibly due to the fact that the cytokine is only induced in RGCswithinjured axons, whereas APP undergoes routine orthograde and retro-
grade transport in all RGC axons, as illustrated by its accumulation on
the distal as well as proximal side of the crush site. Wewould therefore
strongly advocate the use of IL-6 as amarker of ONaxonal transport fail-
ure in future studies. Axonal transport and release of IL-6 has been de-
scribed in cultured cortical neurons treated with IL-1β plus a
depolarizing agent (Tsakiri et al., 2008), but, to our knowledge, this is
the ﬁrst in vivo study to demonstrate that IL-6 is upregulated by injured
neurons and conveyed to the site of axonal injury. Of note, the response
of IL-6 adds further weight to the hypothesis that the ONH is the pivotal
site of RGC injury following moderate elevation of IOP.
Two previous studies in rats have investigated the expression of IL-6
during experimental glaucoma: Sappington and Calkins (2008) used a
chronic mouse model and observed enhanced IL-6 immunolabelling
in the ganglion cell layer, a proportion ofwhichwas associatedwithmi-
croglia, whilst Johnson et al. (2012) made use of the hypertonic saline
rat model and reported a signiﬁcant, early upregulation of IL-6 mRNA
in the ONH. We uncovered no evidence of IL-6 localisation within reti-
nalmicroglia following induction of elevated IOP, althoughwe didmea-
sure a highly signiﬁcant upregulation in overall retinal IL-6 gene
expression. It is logical to infer that the increasedmRNA level was large-
ly due to synthesis byRGCs, but expression by other cell types, including
microglia, is also possible. Regarding the ONH, the cell types responsible
for the elevated IL-6 mRNA measured by Johnson et al. (2011) are un-
known. Since the hypertonic saline model has similar characteristics
and displays a similar pathology to the laser model used herein, we
might anticipate the models would also feature similar pathogeneses.
We were unable to detect any IL-6 immunoreactivity within glial cells
of the ONH and tentatively suggest that the mRNA might be contained
Fig. 8. Localisation of IL-6 to injured RGC axons following (A) ON crush and (B) bilateral occlusion of the common carotid arteries. (A) At 1 day after ON crush, marked accumu-
lations of IL-6, APP and synaptophysin are evident within RGC axons proximal to the lesion (arrows). Accumulations of APP and synaptophysin, but not IL-6 (asterisk), are also
apparent within RGC axons on the distal side of the lesion. By 14 days, many RGC axons remain immunopositive for IL-6, but not for APP. At this time point, the lesion contains
numerous ED1-labelled macrophages. (B) Occlusion of the common carotid arteries causes an infarct (asterisk) in the proximal ON after 2 days, as shown by TUNEL labelling. Sim-
ilar to ON crush, there are marked accumulations of IL-6 and APP within RGC axons proximal to the infarct site. Scale bar: A and B, 100 μm.
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bility that glial cells synthesise IL-6mRNAnor that glial cells release IL-6
which is then taken up by axons.
The stimulus for IL-6 synthesis and axonal transport during exper-
imental glaucoma must arise from axonal injury rather than ocular
hypertension, as the response was identical after ON crush and bilat-
eral occlusion of the carotid arteries, each of which causes damage to
the proximal ON without elevating IOP. This conclusion is supported
by the results of previous studies, which have documented induction
of IL-6 mRNA synthesis in peripheral (Ito et al., 1998; Murphy et al.,
1995, 1999) and central (Hans et al., 1999) neurons in response to ax-
onal injury. The induction of IL-6 mRNA synthesis in peripheral neu-
rons was shown to be prevented by administration of colchicine,
which blocks retrograde axonal transport, to the nerve stump, leading
the authors to conclude that a factor arising from the nerve stump
was responsible (Murphy et al., 1999).
IL-6 is a member of the family of cytokines that all utilise the
signal-transducing receptor subunit, gp130 (Spooren et al., 2011).
To impart perspective on the IL-6 results, we investigated expression
of another family member, CNTF, after ON injury. CNTF is a survival
factor for RGCs after injury and has been shown to be an important
factor involved in RGC axonal regeneration after ON crush (Wen et
al., 2012). In contrast to IL-6, CNTF was localised exclusively to glial
cells in the retina and ONH following induction of ocular hyperten-
sion and ON crush, ﬁndings consistent with previous accounts of
CNTF distribution after excitotoxic and ischemia-reperfusion injuries
(Honjo et al., 2000; Ju et al., 1999). Future work needs to ascertain
the patterns of expression of other gp130 family members subse-
quent to ON injury, in particular Leukemia inhibitory factor, a cyto-
kine that has many similar attributes to IL-6.
The function of IL-6 produced as a consequence of ON injury is pres-
ently unknown. Whilst traditionally viewed as a proinﬂammatorycytokine, interleukin-6 is now known to have numerous roles in the
CNS including as an activator of the immune system (Scheller et al.,
2011), in mediating neuronal differentiation and homeostasis as well
as astrocyte generation (Spooren et al., 2011). Importantly, IL-6 is also
increasingly recognised as exerting neuroprotective, neurotrophic and
neuroregenerative properties. In the peripheral nervous system, numer-
ous studies have shown that IL-6 plays a key role in axonal regeneration
after nerve lesion (see Spooren et al., 2011 for review),whilst in the CNS,
IL-6 promotes sprouting and functional recovery in lesioned hippocam-
pal slice cultures (Hakkoum et al., 2007). Given our results showing,
ﬁrstly, that IL-6 colocalises with Gap43 in some putative regenerating
axons, and secondly, that it stimulates neuritogenesis in adult RGC cul-
tures, it is tempting to speculate that this cytokine plays an important
role in the process whereby RGCs attempt to regenerate their injured
axons. This process of innate attempted regeneration of RGC axons,
which has been demonstrated to occur after ON crush (Benowitz and
Yin, 2008) and experimental glaucoma (Chidlow et al., 2011b), fails at
the site of nerve injury, presumably as a consequence of inhibitory fac-
tors, the maturation state of the neurons in question and the formation
and presence of a glial scar (Berry et al., 2008). Of interest are the results
of a recent study, which showed that endogenous regeneration of RGC
axons after ON crush was enhanced by prior induction of experimental
glaucoma (Lorber et al., 2012). The authors, who used the same experi-
mental glaucoma model as in the present study, provided data consis-
tent with the view that activated retinal glia mediate part of this
response. Given the enhanced IL-6 synthesis that occurs in the present
model, however, we would suggest that this too plays a role. In support
of this view, Streit et al. (2000) analysed regeneration in three different
peripheral axotomymodels, and, the only paradigm that led to regener-
ation showed the highest levels of IL-6 expression and the largest gliosis.
The neuroregenerative role of the gp130 pathway in general, and CNTF
in particular, in the ON has prompted much interest in recent years.
Fig. 9. Relationship between IL-6 and Gap43 expression in rats subjected to experimental glaucoma (A–K) and ON crush (L–N). At 3 days after induction of chronic ocular hyper-
tension, pronounced IL-6 immunolabelling is evident within axons at the ONH (A), but little Gap43 immunoreactivity is detectable (B). By 7 days, Gap43 immunoreactivity at the
ONH is strikingly higher, equalling that of IL-6 or often exceeding it (C–F). At 14 days, intense Gap43 immunoreactivity is typically observed at the ONH, whilst the abundance of
IL-6 has declined markedly (G, H); nevertheless, the two markers colocalise in some putative regenerating ﬁbres, as seen in the lamina of this rat (I–K). At 14 days following ON
crush, axons proximal to the crush site are always Gap43-positive and frequently IL-6 positive, as shown in this representative rat (L–N). neck, neck region of ONH; transition, tran-
sition region of ONH. Scale bar: A–H and L–N, 50 μm; I–K, 25 μm.
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enhances this process in the presence of CNTF, future work needs to
focus more speciﬁcally on the role of IL-6 itself.Fig. 10. Temporal characterisation of the abundance of IL-6 and Gap43 immunoreactivites at
theONH following induction of experimental glaucoma, as determined by semi-quantitative
grading. Values represent mean ± SEM, where n=20 (control), n=7 (1 day), n=9
(3 days), n=13 (7 days), n=21 (14 days).In the present study, we detected intense expression of IL-1β and
TNFα by retinal microglia in response to endotoxin challenge or glu-
tamate excitotoxicity. In contrast, no such effects were observed fol-
lowing elevation of IOP. This was true of the ONH as well as the
retina, andwas the case, irrespective of whether animals were analysed
at early timepoints that correspondedwith axonal transport disruption,
or later time points that featured overt axonal and somal degeneration
together with reactive gliosis. Our negative results are in agreement
with those of Morrison and colleagues, who used microarray analysis
to explore gene expression changes in the ONH of rats subjected to oc-
ular hypertension and reported no evidence of upregulated IL-1β and
TNFα in rats with early (Johnson et al., 2011) or late (Johnson et al.,
2007) injury proﬁles. The present data are also compatible with the re-
sults of Perrin et al. (2005), who compared gene expression in the pe-
ripheral and central nervous systems during Wallerian degeneration
and identiﬁedmarked increases in expression of IL-1β and TNFα in pe-
ripheral nerves, but minimal upregulations in central nerves. However,
our results do not correspond with the ﬁnding of TNFα expression by
ONH glia in human eyes with severe glaucoma (Yuan and Neufeld,
2000). The reason for the difference may simply be that factors other
than ocular hypertension cause glial expression of TNFα during ad-
vanced glaucomatous disease.
Despite not observing IL-1β or TNFα immunolabelling in rats
subjected to elevated IOP,wedid identifymodest but signiﬁcant increases
in expression of both mRNAs in the retina. An increase in retinal TNFα
mRNA of the same order of magnitude has previously been reported in
Fig. 11. IL-6 enhances neuritogenesis in adult RGC cultures. (A, B) Representative images of RGCs in the presence (plus) and absence (minus) of growth factor mix, which was ad-
ditionally supplementated with IL-6 or vehicle. RGCs are shown labelled with Tau (green) to visualise the axonal cytoskeleton and Gap43 (red) to highlight active growth. (C, D)
Analysis of the effect of IL-6 on the number of neurites per cell and the length of the major neurite. Values represent mean±SEM, where n=32. **Pb0.01, *Pb0.05 by Kruskal–
Wallis one-way analysis of variance, followed by Dunn's Multiple Comparison Test.
580 G. Chidlow et al. / Neurobiology of Disease 48 (2012) 568–581an induced mouse model of glaucoma (Nakazawa et al., 2006), although
as with our study the cell types responsible were not identiﬁed. There
are three plausible explanations for the disconnect between the mRNA
and protein results: (1) the mRNAs were not translated; (2) the proteins
were only transiently expressed by individual cells or rapidly degraded,
either scenario of which would make immunohistochemical detection
more challenging; (3) the tissue level of the proteins was below the de-
tectable limit of the relevant assays. In support of the ﬁrst possibility, dis-
crepancies between IL-1β and TNFαmRNA and protein levels have been
widely reported in the literature, as for example in rodent models
of Wallerian degeneration (Shamash et al., 2002), forebrain ischemia
(Sairanen et al., 1997), myocardial infarction (Kaur et al., 2006) and
arthitis (Rioja et al., 2004). One theory that has been proposed to account
for the phenomenon relates to “priming”, inwhich a detrimental stimulus
induces transcription but not translation of a cytokine in a population of
cells, leaving them in a “primed” state. A subsequent detrimental stimula-
tion then results in a rapid, exaggerated release of the cytokine (Schindler
et al., 1990). The second scenario is arguably less convincing. Expression
of IL-1β and TNFα after treatment with LPS or NMDA is transient in na-
ture, yet, immunopositive microglia were detectable in every tissue sec-
tion analysed from every animal. It is implausible that we could have
failed to identify any positive labelling in any animal with experimental
glaucoma. In our opinion, the ﬁnal explanation has the most credibility.
The cytokines are known to be present in very lowquantities under phys-
iological conditions. Although the mRNAs were upregulated maximally
4-fold during ocular hypertension, these increases are modest compared
with typical responses to other injuries. For example, Nakazawa et al.
(2007), measured a 25-fold upregulation of IL-1βmRNA in the rat retina
after NMDA treatment, despite using a substantially lower dose of NMDA
than in thepresent study.Given the far greater sensitivity of real-timePCR
compared to immunohistochemistry, it is entirely feasible that the levels
of both cytokines, although augmented relative to control animals,
remained too low to visualise. Overall, our results do not provide support
for the theory that glial cells secrete IL-1β and TNFα in response to ocular
hypertension; however, they do not contradict previous work in micethat advocates an important role for TNFα in the pathophysiology of
experimental glaucoma (Nakazawa et al., 2006).
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